Results for the fourth quarter and full-year 20 (5) are summarized below. I have never been more confident in the future of Pfizer." Finally, we have prudently deployed our capital through multiple business development transactions in recent months to advance our strategies, always with an eye toward bolstering growth in the latter half of this decade and beyond.
In 2021, we exceeded our goal of manufacturing 3 billion doses of Comirnaty (1), a monumental and unprecedented achievement by our Global Supply colleagues. In addition, we just concluded a year where we provided tremendous value to society, including to both patients and shareholders. Today we are issuing guidance for the coming year which, if achieved, would represent the highest level of annual revenues and Adjusted diluted EPS (3) in Pfizer's long history. As we enter a new year, I look forward to all we will accomplish together."įrank D'Amelio, Chief Financial Officer, Executive Vice President, stated: "As I prepare to retire as CFO of Pfizer, I am proud to see that the company is performing better than at any other time during my nearly 15 years here. Everywhere I look in the company, I see colleagues who are inspired by what we have achieved to date and filled with determination to be part of the next breakthrough that could change the world for patients in need. Bourla continued: "These successes have not only made a positive difference in the world, but I believe they have fundamentally changed Pfizer and its culture forever. Now, less than two years since we made that commitment, we are proud to say that we have delivered both the first FDA-authorized vaccine against COVID-19 (with our partner, BioNTech) and the first FDA-authorized oral treatment for COVID-19."ĭr. We put billions of dollars of capital on the line in pursuit of those goals, not knowing whether those investments would ever pay off. Albert Bourla, Chairman and Chief Executive Officer, stated: "In the early days of the COVID-19 pandemic, we committed to use all of the resources and expertise we had at our disposal to help protect populations globally against this deadly virus, as well as to offer treatments to help avoid the worst outcomes when infections do occur.
Chantix free 30 day trial 2021 update#
The fourth-quarter 2021 earnings presentation and accompanying prepared remarks from management as well as the quarterly update to Pfizer's R&D pipeline can be found on the Pfizer website.ĭr.
In addition, Pfizer raised its previous 2022 revenue guidance for Comirnaty (1), the Pfizer-BioNTech SE (BioNTech) COVID-19 vaccine, and provided for the first time 2022 revenue guidance for its oral COVID-19 treatment, Paxlovid. (NYSE: PFE) reported strong financial results for fourth-quarter and full-year 2021 and provided 2022 total company financial guidance (4). Provides Updates and New Data for Select Clinical Programs Spanning Vaccines, Hospital, Oncology, Rare Disease and Internal Medicine on Analyst Conference Call.Issues Initial 2022 Revenue Guidance for Paxlovid of Approximately $22 Billion, Reflecting Treatment Courses Expected to be Delivered Primarily Under Supply Contracts Signed or Committed as of Late-January.Raises 2022 Revenue Guidance for Comirnaty (1) to Approximately $32 Billion, Reflecting Doses Expected to be Delivered Under Supply Contracts Signed as of Late-January.Provides Full-Year 2022 Record-High Guidance (4) for Revenues of $98.0 to $102.0 Billion and Adjusted Diluted EPS (3) of $6.35 to $6.55, Reflecting 23% and 46% Year-Over-Year Growth at the Midpoints, Respectively.Full-Year 2021 Reported Diluted EPS (2) of $3.85, Adjusted Diluted EPS (3) of $4.42 Fourth-Quarter 2021 Reported Diluted EPS (2) of $0.59, Adjusted Diluted EPS (3) of $1.08.Fourth-Quarter 2021 Revenues of $23.8 Billion, Reflecting 106% Operational Growth Excluding Contributions from Comirnaty (1) and Paxlovid, Revenues Declined 2% Operationally Driven Primarily by the Impact of Fewer Selling Days Compared to the Prior-Year Quarter.
Full-Year 2021 Revenues of $81.3 Billion, Reflecting 92% Operational Growth Excluding Contributions from Comirnaty (1) and Paxlovid, Revenues Grew 6% Operationally to $44.4 Billion.Top Battery Metals Stocks on the TSX and TSXV.
0 kommentar(er)
